Get started
Rhythm Pharmaceuticals, Inc.Rhythm Pharmaceuticals, Inc.Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

RYTM chart


Full chart

RYTM upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.65 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−4.34 USD
Net income (FY)
‪−184.68 M‬ USD
Revenue (FY)
‪77.43 M‬ USD
Shares float
‪54.81 M‬
Beta (1Y)
2.62

Employees


Employees (FY)
226
Change (1Y)
+49 +27.68%
Revenue / Employee (1Y)
‪342.60 K‬ USD
Net income / Employee (1Y)
‪−817.16 K‬ USD

About Rhythm Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
David P. Meeker
Website
rhythmtx.com
Headquarters
Boston
Founded
2008
FIGI
BBG007DLZ601
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

RYTM news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of RYTM is 59.36 USD — it has decreased by −1.02% in the past 24 hours. Watch Rhythm Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Rhythm Pharmaceuticals, Inc. stocks are traded under the ticker RYTM.
RYTM stock has fallen by −7.83% compared to the previous week, the month change is a 14.15% rise, over the last year Rhythm Pharmaceuticals, Inc. has showed a 79.99% increase.
We've gathered analysts' opinions on Rhythm Pharmaceuticals, Inc. future price: according to them, RYTM price has a max estimate of 84.00 USD and a min estimate of 58.00 USD. Watch RYTM chart and read a more detailed Rhythm Pharmaceuticals, Inc. stock forecast: see what analysts think of Rhythm Pharmaceuticals, Inc. and suggest that you do with its stocks.
RYTM reached its all-time high on Nov 11, 2024 with the price of 68.58 USD, and its all-time low was 3.04 USD and was reached on May 20, 2022. View more price dynamics on RYTM chart.
See other stocks reaching their highest and lowest prices.
RYTM stock is 4.72% volatile and has beta coefficient of 2.62. Track Rhythm Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Rhythm Pharmaceuticals, Inc. there?
Today Rhythm Pharmaceuticals, Inc. has the market capitalization of ‪3.65 B‬, it has decreased by −0.17% over the last week.
Yes, you can track Rhythm Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Rhythm Pharmaceuticals, Inc. is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
RYTM earnings for the last quarter are −0.73 USD per share, whereas the estimation was −0.80 USD resulting in a 9.27% surprise. The estimated earnings for the next quarter are −0.75 USD per share. See more details about Rhythm Pharmaceuticals, Inc. earnings.
Rhythm Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪33.25 M‬ USD, despite the estimated figure of ‪32.52 M‬ USD. In the next quarter, revenue is expected to reach ‪36.13 M‬ USD.
RYTM net income for the last quarter is ‪−43.64 M‬ USD, while the quarter before that showed ‪−32.26 M‬ USD of net income which accounts for −35.27% change. Track more Rhythm Pharmaceuticals, Inc. financial stats to get the full picture.
No, RYTM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 226.00 employees. See our rating of the largest employees — is Rhythm Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Rhythm Pharmaceuticals, Inc. EBITDA is ‪−263.92 M‬ USD, and current EBITDA margin is −235.83%. See more stats in Rhythm Pharmaceuticals, Inc. financial statements.
Like other stocks, RYTM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Rhythm Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Rhythm Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Rhythm Pharmaceuticals, Inc. stock shows the strong buy signal. See more of Rhythm Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.